Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1997 Dec;65(12):5184–5190. doi: 10.1128/iai.65.12.5184-5190.1997

Human B- and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine.

E R van der Voort 1, H van Dijken 1, B Kuipers 1, J van der Biezen 1, P van der Ley 1, J Meylis 1, I Claassen 1, J Poolman 1
PMCID: PMC175747  PMID: 9393814

Abstract

The PorA protein from Neisseria meningitidis, a potential vaccine candidate, induces human bactericidal antibodies which are serosubtype specific. We developed a hexavalent PorA outer membrane vesicle vaccine based on reference strain H44/76. This vaccine contains the six most prevalent PorA serosubtypes as found in many countries. We previously reported on the immune responses of 20 adult volunteers after a single immunization with this vaccine. In this study, the B- and T-cell responses in three adult volunteers were studied after three consecutive immunizations (0, 2, and 11 months). The first immunization induced a strong B-cell response resulting in high immunoglobulin G levels in an outer membrane vesicle enzyme-linked immunosorbent assay. At least a fourfold increase in bactericidal activity was observed against the majority (four to six) of the vaccine antigens compared to prevaccination titers. Immunodominance was observed for one or two of the PorAs in the bactericidal assay with a set of six isogenic H44/76-derived PorA target strains. These strains carry the individual PorAs as present in the vaccine. The second and third immunizations did not induce a further increase in the immune responses. A decline in time with respect to PorA-specific antibodies was observed after each immunization. These observations were reflected by the T-cell proliferation responses. Two additional sets of isogenic H44/76-derived mutant strains were used to study the specificity and/or cross-reactivity of the induced bactericidal antibodies. These target strains differ only in expressing mutant family variants of either PorA P1.7,16 or P1.5,10, both present in the PorA vesicle vaccine. The bactericidal antibody responses found were directed predominantly against the P1.7 (loop 1 of P1.7,16) and the P1.10 (loop 4 of P1.5,10) epitopes. This indicates that different portions of PorA were involved in the induction of bactericidal antibodies depending upon the PorA serosubtype.

Full Text

The Full Text of this article is available as a PDF (150.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bjune G., Høiby E. A., Grønnesby J. K., Arnesen O., Fredriksen J. H., Halstensen A., Holten E., Lindbak A. K., Nøkleby H., Rosenqvist E. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991 Nov 2;338(8775):1093–1096. doi: 10.1016/0140-6736(91)91961-s. [DOI] [PubMed] [Google Scholar]
  2. Claassen I., Meylis J., van der Ley P., Peeters C., Brons H., Robert J., Borsboom D., van der Ark A., van Straaten I., Roholl P. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine. 1996 Jul;14(10):1001–1008. doi: 10.1016/0264-410x(96)00020-5. [DOI] [PubMed] [Google Scholar]
  3. Finne J., Bitter-Suermann D., Goridis C., Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol. 1987 Jun 15;138(12):4402–4407. [PubMed] [Google Scholar]
  4. Frasch C. E. Status of a group B Neisseria meningitidis vaccine. Eur J Clin Microbiol. 1985 Dec;4(6):533–536. doi: 10.1007/BF02013388. [DOI] [PubMed] [Google Scholar]
  5. Frasch C. E. Vaccines for prevention of meningococcal disease. Clin Microbiol Rev. 1989 Apr;2 (Suppl):S134–S138. doi: 10.1128/cmr.2.suppl.s134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Holten E. Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978. J Clin Microbiol. 1979 Feb;9(2):186–188. doi: 10.1128/jcm.9.2.186-188.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Maiden M. C., Bygraves J. A., McCarvil J., Feavers I. M. Identification of meningococcal serosubtypes by polymerase chain reaction. J Clin Microbiol. 1992 Nov;30(11):2835–2841. doi: 10.1128/jcm.30.11.2835-2841.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. McGuinness B. T., Clarke I. N., Lambden P. R., Barlow A. K., Poolman J. T., Jones D. M., Heckels J. E. Point mutation in meningococcal por A gene associated with increased endemic disease. Lancet. 1991 Mar 2;337(8740):514–517. doi: 10.1016/0140-6736(91)91297-8. [DOI] [PubMed] [Google Scholar]
  9. McGuinness B., Barlow A. K., Clarke I. N., Farley J. E., Anilionis A., Poolman J. T., Heckels J. E. Deduced amino acid sequences of class 1 protein (PorA) from three strains of Neisseria meningitidis. Synthetic peptides define the epitopes responsible for serosubtype specificity. J Exp Med. 1990 Jun 1;171(6):1871–1882. doi: 10.1084/jem.171.6.1871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Mead D. A., Kemper B. Chimeric single-stranded DNA phage-plasmid cloning vectors. Biotechnology. 1988;10:85–102. doi: 10.1016/b978-0-409-90042-2.50010-6. [DOI] [PubMed] [Google Scholar]
  11. Milagres L. G., Ramos S. R., Sacchi C. T., Melles C. E., Vieira V. S., Sato H., Brito G. S., Moraes J. C., Frasch C. E. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun. 1994 Oct;62(10):4419–4424. doi: 10.1128/iai.62.10.4419-4424.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Peeters C. C., Rümke H. C., Sundermann L. C., Rouppe van der Voort E. M., Meulenbelt J., Schuller M., Kuipers A. J., van der Ley P., Poolman J. T. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine. 1996 Jul;14(10):1009–1015. doi: 10.1016/0264-410x(96)00001-1. [DOI] [PubMed] [Google Scholar]
  13. Peltola H. Meningococcal disease: still with us. Rev Infect Dis. 1983 Jan-Feb;5(1):71–91. doi: 10.1093/clinids/5.1.71. [DOI] [PubMed] [Google Scholar]
  14. Poolman J. T. Development of a meningococcal vaccine. Infect Agents Dis. 1995 Mar;4(1):13–28. [PubMed] [Google Scholar]
  15. Rosenqvist E., Høiby E. A., Wedege E., Bryn K., Kolberg J., Klem A., Rønnild E., Bjune G., Nøkleby H. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun. 1995 Dec;63(12):4642–4652. doi: 10.1128/iai.63.12.4642-4652.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rosenqvist E., Høiby E. A., Wedege E., Caugant D. A., Frøholm L. O., McGuinness B. T., Brooks J., Lambden P. R., Heckels J. E. A new variant of serosubtype P1.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies induced by a serogroup B outer membrane protein vaccine. Microb Pathog. 1993 Sep;15(3):197–205. doi: 10.1006/mpat.1993.1070. [DOI] [PubMed] [Google Scholar]
  17. Scholten R. J., Bijlmer H. A., Poolman J. T., Kuipers B., Caugant D. A., Van Alphen L., Dankert J., Valkenburg H. A. Meningococcal disease in The Netherlands, 1958-1990: a steady increase in the incidence since 1982 partially caused by new serotypes and subtypes of Neisseria meningitidis. Clin Infect Dis. 1993 Feb;16(2):237–246. doi: 10.1093/clind/16.2.237. [DOI] [PubMed] [Google Scholar]
  18. Suker J., Feavers I. M., Maiden M. C. Monoclonal antibody recognition of members of the meningococcal P1.10 variable region family: implications for serological typing and vaccine design. Microbiology. 1996 Jan;142(Pt 1):63–69. doi: 10.1099/13500872-142-1-63. [DOI] [PubMed] [Google Scholar]
  19. Tommassen J., Vermeij P., Struyvé M., Benz R., Poolman J. T. Isolation of Neisseria meningitidis mutants deficient in class 1 (porA) and class 3 (porB) outer membrane proteins. Infect Immun. 1990 May;58(5):1355–1359. doi: 10.1128/iai.58.5.1355-1359.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Van Der Ley P., Poolman J. T. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect Immun. 1992 Aug;60(8):3156–3161. doi: 10.1128/iai.60.8.3156-3161.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Wedege E., Dalseg R., Caugant D. A., Poolman J. T., Frøholm L. O. Expression of an inaccessible P1.7 subtype epitope on meningococcal class 1 proteins. J Med Microbiol. 1993 Jan;38(1):23–28. doi: 10.1099/00222615-38-1-23. [DOI] [PubMed] [Google Scholar]
  22. Wyle F. A., Artenstein M. S., Brandt B. L., Tramont E. C., Kasper D. L., Altieri P. L., Berman S. L., Lowenthal J. P. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis. 1972 Nov;126(5):514–521. doi: 10.1093/infdis/126.5.514. [DOI] [PubMed] [Google Scholar]
  23. van der Ley P., Heckels J. E., Virji M., Hoogerhout P., Poolman J. T. Topology of outer membrane porins in pathogenic Neisseria spp. Infect Immun. 1991 Sep;59(9):2963–2971. doi: 10.1128/iai.59.9.2963-2971.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. van der Ley P., van der Biezen J., Hohenstein P., Peeters C., Poolman J. T. Use of transformation to construct antigenic hybrids of the class 1 outer membrane protein in Neisseria meningitidis. Infect Immun. 1993 Oct;61(10):4217–4224. doi: 10.1128/iai.61.10.4217-4224.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. van der Ley P., van der Biezen J., Poolman J. T. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine. 1995 Mar;13(4):401–407. doi: 10.1016/0264-410x(95)98264-b. [DOI] [PubMed] [Google Scholar]
  26. van der Voort E. R., van der Ley P., van der Biezen J., George S., Tunnela O., van Dijken H., Kuipers B., Poolman J. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect Immun. 1996 Jul;64(7):2745–2751. doi: 10.1128/iai.64.7.2745-2751.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES